1 |
Pucci P, Lee L, Han M, Matthews J, Jahangiri L, Manners E, Sorby-adams A, Schlederer M, Kaggie J, Trigg R, Prokoph N, Ducray S, Merkel O, Rifatbegovic F, Luo J, Taschner-mandl S, Kenner L, Burke G, Turner S. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers collateral sensitivity to ALK inhibitors in high-risk neuroblastoma.. [DOI: 10.21203/rs.3.rs-2167328/v1] [Reference Citation Analysis]
|
2 |
Pandey M, Wen PX, Ning GM, Xing GJ, Wei LM, Kumar D, Mayuren J, Candasamy M, Gorain B, Jain N, Gupta G, Dua K. Intraductal delivery of nanocarriers for ductal carcinoma in situ treatment: a strategy to enhance localized delivery. Nanomedicine (Lond) 2022;17:1871-89. [PMID: 36695306 DOI: 10.2217/nnm-2022-0234] [Reference Citation Analysis]
|